Can Botox make Big Pharma attractive? What qualifies as a “cabal”? And will the CRISPR patent fight outlive us all?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we pick apart the proposed merger of AbbVie and Allergan, a pharmaceutical marriage of convenience with vast implications for the drug business. Second, STAT’s Sharon Begley joins us to discuss her story on how scientific dogma thwarted new ideas in Alzheimer’s disease research. Then we dig into a curious bit of biotech marketing that left some key facts unstated. Finally, we embark on a lightning round, featuring CRISPR patents, Democratic candidates, and a pugilistic federal agency.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy